A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE

Phase 1

• Conditions: Crohn's Disease; MedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders; Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

• Registration Number: EUCTR2011-003622-27-DE
• Lead Sponsor: Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03-30
• Last Update Posted: 8 May 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
1. Subjects who complete 26-week maintenance treatment of the A3921084 study or subjects who withdraw early due to A3921084 study treatment failure
2. Women of childbearing potential must test negative for pregnancy prior to study enrolment.
3. Sexually active females of childbearing potential are required to use adequate contraceptive methods during the study period and until completion of the follow-up procedures. No specific contraceptive measures are required in male subjects during study participation (Further description of the requirements and a list of contraceptives considered effective and acceptable for use in this trial are found in Section 4.4 Life Style Guidelines of the protocol).
4. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
5. Evidence of a personally signed and dated informed consent document(s) indicating that the subject has been informed of all pertinent aspects of the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 48
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 12

Exclusion Criteria

Subjects presenting with any of the following will be excluded from the
study:
1. Subjects who have been discontinued due to protocol violation(s) (as
determined by the Sponsor) in the A3921084 study.
2. Subjects who were discontinued from the A3921084 study due to an
adverse event that was not related to Crohn's disease.
3. Evidence of active (draining) fistulae, intrabdominal or perineal
collection or abscess at Baseline (MRI imaging is not required for entry
to this study unless clinically indicated).
4. Subjects with evidence of or suspected liver disease ie, liver injury
due to methotrexate or primary sclerosing cholangitis.
5. Subjects with evidence of blood dyscrasias at Baseline visit (as
assessed by the laboratory results from Week 26 or early discontinuation
visit from the A3921084 study):
• Hemoglobin levels <9.0 g/dL
• An absolute white blood cell (WBC) count of <3.0 x 10 to the power of
9/L (<3000/mm3) or absolute neutrophil count of <1.2 X 10 to the
power of 9/L (<1200/mm3) or absolute lymphocyte count of <0.5 x 10
to the power of 9/L (<500/mm3).
• Thrombocytopenia, as defined by a platelet count <100 x 10 to the
power of 9/L (<100,000/mm3).
6. Subjects who have been scheduled to receive any live or attenuated
virus vaccination during study period and for 6 weeks after last dose of
study drug. (see Section 4.4.4 of the protocol for further information on
avoidance of household contacts who may be vaccinated with live virus).
7. Women who are pregnant or breastfeeding or planning pregnancy
during the study period.
8. Subjects with estimated GFR =40 mL/min based on Cockcroft-Gault
calculation from Week 26 or early discontinuation visit from the
A3921084 study.
9. Subjects with total bilirubin, AST or ALT more than 1.5 times the
upper limit of normal from Week 26 or early discontinuation visit from
the A3921084 study.
10. Subjects with current or recent history of severe, progressive, or
uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic
(including uncontrolled hypercholesterolemia), endocrine, pulmonary,
cardiac, or neurological disease.
11. Baseline 12-lead ECG (from Week 26 or early discontinuation visit
from the A3921084 study) that demonstrates clinically relevant
abnormalities which may affect subject safety or interpretation of study
results (ie, baseline QTcF >450 ms, complete LBBB, acute or
indeterminate age myocardial infarction, 2nd-3rd degree AV block, or
serious bradyarrhythmias or tachyarrhythmias; see Appendix 3 of the
protocol).
12. Subjects who are expected to receive prohibited concomitant
medications (see Appendix 2 of the protocol) including medications that
are either moderate to potent CYP3A4 inducers or inhibitors during the
study period.
13. Subjects who, in the opinion of the investigator or Pfizer, will be
uncooperative or unable to comply with study procedures.
14. Subjects who are investigational site staff members or relatives of
those site staff members or subjects who are Pfizer employees directly
involved in the conduct of the trial.15. Other severe acute or chronic medical or psychiatric condition or
laboratory abnormality that may increase the risk associated with study
participation or investigational product administration or may interfere
with the interpretation of study results and, in the judgment of the
investigator, would make the subject inappropriate for entry into this
study.
16. Subjects who are participating in or interested in participating in
other investig

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified